5.76
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
Vir Biotechnology Begins Phase 1 Trial for VIR-5525 - TipRanks
Vir Biotechnology doses first patient in EGFR-targeted cancer trial By Investing.com - Investing.com South Africa
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors - Yahoo Finance
Vir Biotechnology Inc. Stock Analysis and ForecastExceptional return forecasts - Autocar Professional
What drives Vir Biotechnology Inc. stock priceUnstoppable investment returns - Autocar Professional
Vir Biotechnology: Hep B And Cancer Projects March On (NASDAQ:VIR) - Seeking Alpha
Have Insiders Sold Vir Biotechnology Shares Recently? - simplywall.st
What analysts say about Vir Biotechnology Inc. stockRapidly expanding wealth - jammulinksnews.com
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025 - Business Wire
Is Vir Biotechnology Inc. a good long term investmentSuperior investment outcomes - jammulinksnews.com
(VIR) Investment Analysis and Advice - news.stocktradersdaily.com
Vir Biotechnology EVP Eisner sells $57k in stock By Investing.com - Investing.com Canada
Biotech IPO For The Week Ahead - RTTNews
Raymond James Initiates Vir Biotechnology(VIR.US) With Buy Rating, Announces Target Price $12 - 富途牛牛
Where Vir Biotechnology Stands With Analysts - Benzinga
Raymond James Initiates Vir Biotechnology at Outperform With $12 Price Target - MarketScreener
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Unraveling Vir Biotechnology's 10.6% Spike: A Technical Deep Dive - AInvest
Unraveling Vir Biotechnology's 8.8% Surge: A Deep Dive - AInvest
How to Take Advantage of moves in (VIR) - news.stocktradersdaily.com
Vir Biotechnology Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution - simplywall.st
Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Long Term Trading Analysis for (VIR) - news.stocktradersdaily.com
Transcript : Vir Biotechnology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04 - MarketScreener
(VIR) Trading Advice - news.stocktradersdaily.com
Vir Biotechnology director Janet Napolitano sells $16,148 in stock - Investing.com Australia
Vir Biotechnology director Janet Napolitano sells $16,148 in stock By Investing.com - Investing.com UK
Vir Biotechnology Holds 2025 Annual Stockholder Meeting - TipRanks
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - BioSpace
Vir Biotechnology to Participate in the Goldman Sachs 46th Annua - GuruFocus
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | VIR Stock News - GuruFocus
Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology - Investing.com
Gilead Ready To Go After Hepatitis D Again - insights.citeline.com
Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):